Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- About
Anbio Biotechnology Class A Ordinary Shares (NNNN)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/14/2025: NNNN (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
0 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
Analysis of Past Performance
Type Stock | Historic Profit 564.99% | Avg. Invested days 62 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  5.0 | Stock Returns Performance  5.0 |
| Profits based on simulation | Last Close 08/14/2025 |
Key Highlights
Company Size ETF | Market Capitalization 0 USD | Price to earnings Ratio - | 1Y Target Price - |
Price to earnings Ratio - | 1Y Target Price - | ||
Volume (30-day avg) - | Beta - | 52 Weeks Range 5.18 - 37.08 | Updated Date 05/15/2025 |
52 Weeks Range 5.18 - 37.08 | Updated Date 05/15/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) - |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) - | Return on Equity (TTM) - |
Valuation
Trailing PE - | Forward PE - | Enterprise Value - | Price to Sales(TTM) - |
Enterprise Value - | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA - | Shares Outstanding - | Shares Floating - |
Shares Outstanding - | Shares Floating - | ||
Percent Insiders - | Percent Institutions - |
Upturn AI SWOT
Anbio Biotechnology Class A Ordinary Shares
Company Overview
History and Background
Anbio Biotechnology, established in 2004, focuses on developing and commercializing in-vitro diagnostic (IVD) products. Initially focused on infectious disease testing, it has expanded into other diagnostic areas, including Point of Care Testing (POCT) and immunoassay platforms.
Core Business Areas
- In-Vitro Diagnostics (IVD): Development, manufacturing, and sales of diagnostic test kits used to analyze human samples, like blood and urine, for various diseases and conditions. Testing ranges from infectious diseases to cardiac markers.
- Point of Care Testing (POCT): Development of rapid, portable diagnostic devices for use at or near the patient, providing quick results for immediate clinical decision-making. This encompasses a range of products including rapid immunofluorescence assays.
- Immunoassay Platforms: Offering products in the immunoassay sector utilizing various detection methods, and catering to different diagnostic testing needs.
Leadership and Structure
Details on the leadership team are not extensively publicly available. Typically, a biotech company of this size would have a CEO, CFO, CSO, and a board of directors. Organizational structure includes research and development, manufacturing, sales and marketing, and regulatory affairs departments.
Top Products and Market Share
Key Offerings
- Rapid Diagnostic Tests (RDTs): Anbio offers a portfolio of RDTs focused on infectious diseases and acute care conditions, which includes tests for influenza, COVID-19, and cardiac markers. Market share data specific to Anbio's RDTs is not widely available, but the overall RDT market is competitive. Competitors include Abbott (ABT), Roche (ROG), and QuidelOrtho (QDEL).
- Automated Immunoassay Analyzers: Anbio also develops and markets automated immunoassay analyzers designed for use in clinical laboratories. These systems are designed to process a variety of diagnostic assays. Competitors include Siemens Healthineers (SIEGY), Beckman Coulter (DHR), and Roche (ROG).
Market Dynamics
Industry Overview
The IVD market is experiencing substantial growth driven by increased prevalence of chronic diseases, advancements in diagnostic technologies, and a growing demand for personalized medicine. The POCT segment is benefiting from a shift towards decentralized healthcare and rapid diagnosis.
Positioning
Anbio Biotechnology positions itself as an innovative player in the IVD and POCT markets, focusing on developing cost-effective and high-performance diagnostic solutions, with a focus on the China market. Competitive advantages likely include local market expertise and cost-effective manufacturing.
Total Addressable Market (TAM)
The global IVD market is estimated to reach hundreds of billions of dollars. Anbio's positioning in the China market and expansion plans place it to capitalize on a portion of this substantial TAM.
Upturn SWOT Analysis
Strengths
- Innovative diagnostic technologies
- Strong presence in the China market
- Cost-effective manufacturing capabilities
- Expanding product portfolio
Weaknesses
- Limited brand recognition outside of China
- Dependence on regulatory approvals
- Limited financial resources compared to larger competitors
- Potential for product recalls
Opportunities
- Expansion into new international markets
- Strategic partnerships and collaborations
- Growing demand for POCT solutions
- Development of new diagnostic assays
Threats
- Intense competition from established players
- Changing regulatory landscape
- Economic downturn impacting healthcare spending
- Technological disruptions
Competitors and Market Share
Key Competitors
- ABT
- ROG.SW
- QDEL
- DHR
Competitive Landscape
Anbio faces intense competition from larger, well-established players in the IVD and POCT markets. Its competitive advantages include local market expertise and cost-effective manufacturing. It must continue to innovate and expand its product portfolio to maintain its competitive position.
Growth Trajectory and Initiatives
Historical Growth: Historical growth is difficult to assess without specific financial data, but the company's focus on expanding its product portfolio and geographic reach suggests a positive growth trajectory.
Future Projections: Future growth depends on successful product launches, regulatory approvals, and expansion into new markets. Analyst estimates are not available due to the limited coverage of this specific ADR.
Recent Initiatives: Recent initiatives likely include expanding its product portfolio through R&D, seeking regulatory approvals for new products, and forming strategic partnerships to expand its market presence.
Summary
Anbio Biotechnology shows promise in the in-vitro diagnostics market, particularly within China, benefiting from growing demand for rapid and cost-effective testing solutions. While the company faces stiff competition and regulatory hurdles, its focus on innovation and strategic partnerships could drive future growth. A key challenge will be increasing brand recognition and distribution outside of its core market. Access to comprehensive financial data is limited, making a definitive assessment difficult.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Website
- Industry Reports
- Market Research Reports
- Public Filings
Disclaimers:
The information provided is for informational purposes only and should not be construed as investment advice. Financial data may be limited and may not be fully representative of the company's performance. Market share data is based on estimates and may vary.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Anbio Biotechnology Class A Ordinary Shares
Exchange NASDAQ | Headquaters - | ||
IPO Launch date 2025-02-19 | CEO - | ||
Sector Healthcare | Industry Medical Instruments & Supplies | Full time employees 27 | Website https://www.anbio.com |
Full time employees 27 | Website https://www.anbio.com | ||
Anbio Biotechnology provides in vitro diagnostics (IVD) products in the European Union, the Asia Pacific, North America, South America, Africa, and internationally. It offers SARS-CoV-2 antigen rapid and SARS-CoV-2/influenza A/B antigen rapid tests; and lateral flow immunoassay, fluorescence immunoassay, loop-mediated isothermal amplification, chemiluminescence immunoassay, and reverse-transcription polymerase chain reaction products. It serves over-the-counter, point-of-care testing, and laboratory markets. The company was incorporated in 2021 and is based in Frankfurt am Main, Germany.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.